Humulin I Kwikpen (Isophane)

Humulin I Kwikpen (Isophane) is a pre‑filled, subcutaneous insulin pen that contains insulin human as its active ingredient. Marketed in the European Union as a prescription‑only product, the disposable Kwikpen delivers intermediate‑acting insulin for basal glucose control. It is intended for use by patients with diabetes under the supervision of a healthcare professional. The device allows for accurate dosing and convenient administration without the need for separate syringes.

Humulin I Kwikpen is indicated for the management of blood glucose in adults and children with diabetes.

- Type 1 diabetes mellitus requiring basal insulin support. - Type 2 diabetes mellitus when basal insulin is needed as part of a treatment regimen. - Adjunct therapy in combination with rapid‑acting insulin for mixed‑meal coverage. - Use in patients who need a predictable intermediate‑acting insulin profile.

Like other insulin products, Humulin I Kwikpen may be associated with adverse reactions that vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Injection site reactions such as redness, swelling, or itching. - Lipodystrophy at the injection site, presenting as lipoatrophy or lipohypertrophy. - Transient weight gain due to improved glycemic control.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including urticaria, angioedema, or anaphylaxis. - Edema or heart failure exacerbation in susceptible patients.

Healthcare professionals should consider several precautions when prescribing Humulin I Kwikpen to ensure safe and effective use.

- Assess renal and hepatic function, as impairment may alter insulin clearance. - Monitor blood glucose regularly to avoid hypoglycemia, especially during dose changes. - Use caution in patients with cardiovascular disease or heart failure, as fluid retention can occur. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Educate patients on proper injection technique and rotation of sites to reduce lipodystrophy. - Review concomitant medications that may mask hypoglycemia symptoms.

Humulin I Kwikpen can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid: - Concurrent use of other insulin products without dose adjustment, which may cause severe hypoglycemia. - Beta‑blockers that can blunt hypoglycemia warning signs.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Corticosteroids, which may raise blood glucose and require insulin dose adjustments. - Diuretics, especially thiazides, that can affect electrolyte balance and glucose levels. - Alcohol consumption, which can unpredictably potentiate or mask hypoglycemia.